52 Pages Posted: 12 Sep 2007
Date Written: August 2007
Policy makers need reliable estimates of direct costs of pharmaceutical R&D, in order to contain health-care costs and at the same time maintain a supportive environment for investment in research.
This paper evaluates the application of parametric estimating methods to the late stage clinical development of new drugs, in order to estimate the direct costs of clinical trials from the linear relationship of two non-cost variables: the standardised minimal significant clinical outcome and the sample-size required to reach statistical significance. The number of patients enrolled in clinical trials represents the closest proxy to the total cost of clinical research, as the protocol requirements of randomised studies minimise the cost differences among therapeutic areas.
The first example of randomised experimental research in Life Science cost accounting; this study can be duplicated by virtually anyone who can access a scientific library, without the significant constraint of obtaining proprietary information from pharmaceutical companies.
Keywords: valuation, intangible, assets, pharmaceutical, development, cost
JEL Classification: L65, O32
Suggested Citation: Suggested Citation
Favato, Giampiero and Mills, Roger, Valuation of Intangible Assets: Estimating Late-Stage Development Cost of Pharmaceutical R&D (August 2007). Available at SSRN: https://ssrn.com/abstract=1012639 or http://dx.doi.org/10.2139/ssrn.1012639